Zacks Investment Research upgraded Otonomy Inc (NASDAQ:OTIC) to Hold in a report released today.
- Updated: January 11, 2017
Zacks Investment Research has upgraded Otonomy Inc (NASDAQ:OTIC) to Hold in a report released on Thursday January 12, 2017.
Yesterday Otonomy Inc (NASDAQ:OTIC) traded -5.68% lower at $16.60. The company’s 50-day moving average is $16.86 and its 200-day moving average is $16.49. The last stock close price is up 0.66% from the 200-day moving average, compared to the S&P 500 which has decreased -0.05% over the same time. 0 shares of the stock were exchanged, down from an average trading volume of 157,998
See Chart Below
Otonomy Inc has a 52 week low of $10.50 and a 52 week high of $21.23 The company’s market cap is currently $0.
About Otonomy Inc (NASDAQ:OTIC)
Otonomy, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics for diseases and disorders of the ear. The Company has developed a technology referred to as sustained-exposure that is designed to deliver drug that is retained in the ear for an extended period of time following a local administration. Its product candidates include OTIPRIO, OTO-104 and OTO-311. The Company's product candidate, OTIPRIO, is used for the treatment of pediatric patients with bilateral otitis media with effusion undergoing tympanostomy tube placement (TTP) surgery. Its product candidate, OTO-104, is a sustained-exposure formulation of the steroid dexamethasone in development for the treatment of Meniere's disease and other inner ear conditions. The Company's product candidate, OTO-311, is a sustained-exposure formulation of the N-Methyl-D-Aspartate (NMDA) receptor antagonist gacyclidine in development for the treatment of tinnitus.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.